Xeris pharmaceuticals, inc. (XERS)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Net sales

0

-

-

-

0

-

-

-

-

-

-

Grant and other income

959

1,095

1,688

1,956

2,461

2,423

0

0

0

0

0

Cost of goods sold

0

-

-

-

0

-

-

-

-

-

-

Service revenue

-

-

95

86

-

-

0

0

0

0

0

Cost of revenue

-

-

33

23

-

-

0

0

0

0

0

Gross profit (loss)

869

1,119

1,659

1,928

2,450

2,423

0

0

0

0

0

Operating expenses
Research and development

53,917

60,438

60,408

55,765

45,109

40,654

0

0

0

0

0

Selling, general and administrative

72,149

63,061

47,069

36,691

0

-

0

0

-

-

-

Selling, general and administrative

-

-

-

-

-

-

-

-

0

0

0

Total operating expenses

126,066

123,499

111,552

96,682

75,501

61,767

0

0

0

0

0

Loss from operations

-125,197

-122,380

-109,893

-94,754

-73,051

-59,344

0

0

0

0

0

Other income (expense)
Interest and other income

2,576

2,813

2,990

2,795

2,188

1,613

0

0

0

0

0

Interest expense

6,763

7,163

-1,679

1,091

1,591

2,500

0

0

0

0

0

Change in fair value of warrants

-1,109

-692

281

636

438

-196

0

0

0

0

0

Other expense

-

-

-

-

-

-

-

-

-

-

0

Total other income (expense)

-4,748

-3,658

-3,024

-94

-399

-736

0

0

0

0

-

Net loss before provision for/benefit from income taxes

0

-

-

-

0

-

-

-

-

-

-

Provision for/benefit from income taxes

0

-

-

-

0

-

-

-

-

-

-

Net loss

-129,487

-125,580

-112,917

-94,848

-73,450

-60,080

0

0

0

0

0

Other comprehensive income (loss), net of tax
Unrealized gains on investments

0

-

-

-

0

-

-

-

-

-

-

Foreign currency translation adjustments

0

-

-

-

0

-

-

-

-

-

-

Unrealized gains (losses) on investments

-

-

103

68

-

-

0

0

0

0

-

Comprehensive loss

-129,426

-125,485

-112,814

-94,780

-73,451

-60,132

0

0

0

0

-

Net loss per common share - basic and diluted

-0.89

-1.24

-1.22

-1.28

-1.07

4.28

-0.71

-3.07

-5.49

-3.72

-2.59

Weighted average common shares outstanding, basic and diluted

32,790

27,048

26,942

26,889

23,561

21,068

20,714

4,231

2,169

2,024

2,022